Don't Neglect the Rare Adverse Event with Intravenous Immunoglobulin: Hemolytic Anemia.

[1]  J. Jacobs,et al.  Intravenous Immunoglobulin-Associated Hemolytic Anemia. , 2020, Laboratory medicine.

[2]  M. Mohamed.  Intravenous immunoglobulin-associated hemolysis: risk factors, challenges, and solutions , 2016 .

[3]  R. Berg,et al.  Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012 , 2015, Transfusion.

[4]  R. Padmore.  Possible mechanisms for intravenous immunoglobulin–associated hemolysis: clues obtained from review of clinical case reports , 2015, Transfusion.

[5]  D. Vu,et al.  Intravenous immune globulin–related hemolysis: comparing two different methods for case assessment , 2015, Transfusion.

[6]  K. Willimann,et al.  Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products , 2015, Transfusion.

[7]  J. Pendergrast,et al.  The role of inflammation in intravenous immune globulin–mediated hemolysis , 2015, Transfusion.

[8]  D. Branch,et al.  Anti‐A and anti‐B: what are they and where do they come from? , 2015, Transfusion.

[9]  M. Murphy,et al.  Intravenous immunoglobulin‐induced haemolysis: a case report and review of the literature , 2014, Transfusion medicine.

[10]  J. Dantal.  Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk , 2013, American Journal of Nephrology.

[11]  R. Scuccimarri,et al.  Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases , 2012, Pediatric Rheumatology.

[12]  R. Padmore.  Hemolysis upon intravenous immunoglobulin transfusion. , 2012, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[13]  F. Andersohn,et al.  Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study , 2011, British journal of haematology.

[14]  S. Jordan,et al.  Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[15]  R. Padmore,et al.  Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis , 2008, Transfusion.

[16]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[17]  A. Angiolillo,et al.  IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life , 2004, Thrombosis and Haemostasis.

[18]  P. Schiff,et al.  Blood-group antibodies in human immune serum globulin. , 1972, New England Journal of Medicine.